Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience☆☆This study was sponsored by Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, and Aventis Pharma, Bridgewater, New Jersey.

Sorensen, O.H, Crawford, G.M, Mulder, H, Hosking, D.J, Gennari, C, Mellstrom, D, Pack, S, Wenderoth, D, Cooper, C, Reginster, J.-Y · 2003 · Bone

Abstract

Limited placebo-controlled data are available to assess the long-term fracture efficacy of bisphosphonates. In order to determine the effects of 5 years of risedronate treatment, we extended a 3-year, placebo-controlled vertebral fracture study in osteoporotic women for an additional 2 years; women who entered the extension study continued to receive 5 mg risedronate or placebo according to the original randomization, with maintenance of blinding. End points included vertebral and nonvertebral fracture assessments, bone mineral density measurements, and changes in biochemical markers of bone turnover. A total of 265 women (placebo, 130; 5 mg risedronate, 135) entered the study extension and 220 (83%) completed the additional 2 years. Fracture results observed in the study extension were consistent with those observed in the first 3 years. The risk of new vertebral fractures was significantly reduced with risedronate treatment in years 4 and 5 by 59% (95% confidence interval, 19 to 79%, P = 0.01) compared with a 49% reduction in the first 3 years. Rapid and significant decreases in markers of bone turnover observed in the first 3 years were similarly maintained in the next 2 years of treatment. Increases in spine and hip bone mineral density that occurred in the risedronate group during the first 3 years were maintained or increased with a further 2 years of treatment. The mean increase from baseline in lumbar spine BMD over 5 years was 9.3% (P < 0.001). This study demonstrate…

Overview

Integrity signals

Registry

Crossref · 10.1016/s8756-3282(02)00946-8

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 12 references

Research works printed but not linked: 1

  1. Eastell, 2000, The effects of raloxifene on incident vertebral fractures in postmenopausal women with osteoporosis, J Bone Miner Res, 15, S229

Cited by

See all 254

Metadata

Authors
Sorensen, O. H., Crawford, G. M., Mulder, H., Hosking, D. J., Gennari, C., Mellstrom, D., Pack, S., Wenderoth, D., Cooper, C., & Reginster, J.-Y.
Affiliations
  • Nottingham City Hospital (GB)
  • University of Siena (IT)
  • Procter & Gamble (United Kingdom) (GB)
  • University of Southampton (GB)
  • University of Liège (BE)
Venue
Bone
Publisher
Elsevier BV
Published
2003-02
Volume
32
Issue
2
Pages
120-126
ISSN
  • 1873-2763 (ISSN-L)
  • 8756-3282
OpenAlex
W2125721609
Cited by
254
References
12
Citations by year
2026: 1 · 2025: 2 · 2023: 2 · 2022: 4 · 2021: 1 · 2020: 7 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 10 · 2015: 7 · 2014: 4 · 2013: 13 · 2012: 10
FWCI
30.64
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Bone (publishedVersion)
  • PubMed (publishedVersion)
  • ePrints Soton (University of Southampton) (submittedVersion)
  • Open Repository and Bibliography (University of Liège) (submittedVersion)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords
risedronate, bisphosphonates, osteoporosis, vertebral fractures, non-vertebral fractures, bone mineral density, bone turnover markers, long-term treatment efficacy, postmenopausal women, hip bone density, lumbar spine
MeSH terms
Aged, Aged, 80 and over, Female, Humans, Risk Factors, Etidronic Acid, Time, Bone Density, Osteoporosis, Postmenopausal, Confidence Intervals, Spinal Fractures, Statistics, Nonparametric

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience☆☆This study was sponsored by Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, and Aventis Pharma, Bridgewater, New Jersey. https://app.cochat.ai/papers/10.1016/s8756-3282(02)00946-8
The paper
Sorensen, O. H., Crawford, G. M., Mulder, H., Hosking, D. J., Gennari, C., Mellstrom, D., Pack, S., Wenderoth, D., Cooper, C., & Reginster, J.-Y. (2003). Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience☆☆This study was sponsored by Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, and Aventis Pharma, Bridgewater, New Jersey. Bone. https://doi.org/10.1016/s8756-3282(02)00946-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.